Editorials

Subacute Sclerosing Panencephalitis in Older Adulthood

Ravindra Kumar Garg*, Praveen Kumar Sharma, Neeraj Kumar & Shweta Pandey

Department of Neurology, King George Medical University, Uttar Pradesh, Lucknow, IN

In Response to:
Reyes AJ, Ramcharan K, Perot S, Giddings SL, Rampersad F, Gobin R. Subacute Sclerosing Panencephalitis Causing Rapidly Progressive Dementia and Myoclonic Jerks in a Sexagenarian Woman. Tremor Other Hyperkinet Mov. 2019; 9. doi: 10.7916/tohm.v0.680

Keywords: Dementia, Encephalitis, Adult onset-SSPE, Measles, Myoclonus

Citation: Garg RK, Sharma PK, Kumar N, Pandey S. Subacute Sclerosing Panencephalitis in Older Adulthood. Tremor Other Hyperkinet Mov. 2019; 9. doi: 10.7916/tohm.v0.719

*To whom correspondence should be addressed. E-mail: garg50@yahoo.com

Editor: Ruth Helen Walker, Mount Sinai School of Medicine, USA

Received: August 14, 2019; Accepted: August 19, 2019; Published: September 10, 2019

Copyright: © 2019 Garg et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original authors and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.

Funding: None.

Financial Disclosures: None.

Conflicts of Interest: The authors report no conflicts of interest.

Ethics Statement: Not applicable for this category of article.

Subacute sclerosing panencephalitis (SSPE) is a devastating brain disorder that typically affects children and adolescents. SSPE is caused by persistent measles virus infection. The mechanisms that facilitate the measles virus entering the brain, and persisting and proliferating there for very long periods are not precisely known. Once inside the brain, the measles viral genome undergoes a series of mutations, particularly in the M and F protein genes. These mutations are considered responsible for viral persistence and transneuronal spread inside the brain. Measles viral genome isolated from human brain tissues demonstrates clustered mutations in the virus genome, particularly in the M gene. These mutations destroy the structure and functioning of the encoded proteins. Complete infectious virus particle has rarely been demonstrated in the brain tissue.1 In the brain, the mutated measles virus triggers an intense inflammatory reaction that leads neuron destruction.

SSPE usually affects children. The incidence of SSPE in any population is roughly proportional to that of measles. Developed countries have observed a considerable decline in the occurrence of new SSPE cases following implementation of universal vaccination programs against measles. A World Health Organization expert committee reviewed the epidemiology of SSPE and observed that approximately 4–11 cases of SSPE occur per 100,000 cases of measles.2 The risk of SSPE is much higher with measles infection occurring very early in life (less than 2 years of age).2 Many South East Asian countries, like India and Pakistan, seem to have a very high incidence of SSPE. In developed, resource-rich nations, re-emergence of SSPE is recorded after outbreaks of measles, following a period of excellent measles control.1

Clinically, SSPE is characterized by diffuse encephalitis. Characteristic clinical manifestations area declines in cognitive function, periodic myoclonus, gait abnormalities, vision loss, and lastly a vegetative state. Ocular complications such as chorioretinitis, optic atrophy, papillitis, papilledema, visual field defects, and cortical blindness are frequently heralding manifestations of SSPE.1

Electroencephalography (EEG) shows periodic stereotyped discharges and is virtually pathognomonic of SSPE. Neuroimaging is often nonspecific; however, periventricular white matter signal changes are a characteristic magnetic resonance imaging (MRI) abnormality. In the late stages of disease, there is marked cerebral atrophy. A definite diagnosis of SSPE is made if elevated measles antibodies are demonstrated in cerebrospinal fluid. Currently, there is no effective treatment available for SSPE.1

SSPE in adults is unusual and often presents with atypical features. In a series of 39 adult-onset cases of SSPE, in addition to myoclonus, behavioral changes, seizures, and cognitive issues, visual and extrapyramidal disturbance were common presenting manifestations. In this study, mean age at diagnosis was approximately 21 years (range 18–43 years).3 We reviewed all published cases of SSPE where the age of onset was greater than 35 years. Behavioral changes and deterioration of mental status were the commonest presentations. Vision loss was the next most commonly encountered symptom. Periodic myoclonus and periodic EEG discharges were not consistently present. MRI consistently demonstrated T2 hyperintensities in the periventricular region, predominantly affecting the occipitoparietal lobes (Table 1).414 Creutzfeldt–Jakob disease and anti-N-methyl-D-aspartate-receptor encephalitis are often close differential diagnoses. The demonstration of elevated CSF antimeasles antibody titer and brain biopsy helps in establishing the diagnosis of SSPE. In six patients, histopathological findings of autopsied/biopsied brain were available. In three cases, components of measles virus genome, in brain tissue, were demonstrated (Table 1).7,8,10

Table 1. A review of adult-onset subacute sclerosing panencephalitis

Based upon a PubMed search and review of all cases of subacute sclerosing panencephalitis where the age of onset was greater than 35years.

Reference Country Age/sex Duration of illness Clinical presentation Myoclonus EEG Neuroimaging Treatment Outcome Basis of diagnosis
Reyes et al 20194 Trinidad and Tobago, (West Indies) 62/F six months Rapidly progressive dementias Present Intermittent slow delta wave activity Asymmetric multiple T2 hyperintensities Interferon and isoprinosine Mild improvement Elevated CSF antimeasles antibody titre
Gokoglu and Gozdas 20195 Turkey 62/F 3 years Behavioural changes and deterioration of mental status Absent Diffuse background slowing Subcortical and periventricular deep white matter signal changes Amantadine 300/day Some improvement Elevated CSF antimeasles antibody titre
Elmali et al. 20186 Turkey 61/F 2 years Behavioural, cognitive changes and seizures Subtle Periodic generalized complexes Old cerebral, thalamic and brainstem infarcts Symptomatic Not available Elevated CSF antimeasles antibody titre
Tanaka et al. 19877 Japan 52/M 4 years Rapidly progressive mental deterioration Present Periodic discharges Not available Not available Died Elevated CSF antimeasles antibody titre.
Brain-biopsy: neuronal loss, glial proliferation, and perivascular lymphocytic cuffing. Numerous intranuclear inclusions
nucleocapsids of paramyxovirus
Studart Neto et al. 20158 Brazil 50/M 8 years Behavioural changes and deterioration of mental status Absent Diffuse background slowing Hyperintense lesions involving subcortical, deep hemispheric, and pontine white matter Not available After 15 months, the patient was in a vegetative state Brain biopsy
staining for measles was positive in neuronal, astrocyte, oligodendrocyte and lymphocyte
Gagnon and Bouchard 20039 Canada 49/M 2 years Behavioural changes and progressive cognitive impairment Present Periodic sharp and slow-wave discharges Hyperintensities in both periventricular and subcortical white matter High-dose intrathecal interferon alfa and oral isoprinosine for 6 weeks Continuous deterioration Elevated CSF antimeasles antibody titre
Croxson et al. 200210 Australia 43/M 3 years Vision loss and cognitive decline Irregular delta activity White-matter changes and focal tissue loss in the medial occipital lobes and inferior left parietal lobe Corticosteroids Died Elevated CSF antimeasles antibody titre.
Brain biopsy Measles virus RNA found in brain, spinal cord and eye
Dubois et al 200511 Belgium 42/F 4 years Severe cognitive deficit, ataxia and spasticity Absent Diffuse slowing Multiple confluent periventricular hyperintensities Not available Not available Elevated CSF antimeasles antibody titre
Baillif et al. 201212 France 39 M 3 years Chorioretinitis 3 years before behavioural changes and deterioration of mental status Absent Nonspecific generalized slowing Parieto-occipital signal changes Isoprinosine, Interferon Alpha, and ribavirin Rapid progression to death in 3 months Elevated CSF antimeasles antibody titre
Frings et al. 200213 Germany 39/F 3 years Progressive cognitive impairment Absent Normal Progressive generalized cerebral atrophy Not available Not available Elevated CSF antimeasles antibody titre
Jeevagan and Dissanayake 201714 Sri Lanka 36/M 2 years Chorioretinitis 2 years before behavioural changes and deterioration of mental status Absent Generalised intermittent slowing T2 hyperintensities in periventricular region predominantly affecting the occipitoparietal lobes Short course of oral corticosteroids No improvement Elevated CSF antimeasles antibody titre

Reyes and colleagues reported a 62-year-old woman who presented with rapidly progressive dementia and myoclonus and was later diagnosed as having SSPE.4 This is one of the three oldest recorded patients with SSPE. There are two additional earlier reports of SSPE where patients presented after the age of 60 years.5,6 All these three cases presented with progressive cognitive decline.

Measles is still common in many developing countries, particularly in Africa and Asia. In 2017, the world has seen approximately 110,000 measles-related deaths. Even in developed, resource-rich countries, periodic outbreaks of measles take place. In 2019, the World Health Organization received a report of 112,163 measles cases from 170 countries.15 Measles was declared eliminated from the United States in 2000, although there have been recent outbreaks. It is likely that many new cases of adult-onset SSPE, particularly in older adults, will continue to be reported from all parts of world, including developed countries.

Many antiviral and immune modulator drugs like isoprinosine, interferon-alpha, and ribavirin are used to stabilize the course of disease. Patients with SSPE die within 1–3 years of diagnosis. In acute fulminant SSPE, patients die much earlier. Many genetic mutations in the measles fusion (F) protein change it to a biologically active fusogenic form of the F protein. The fusogenic form of the F protein facilitates transneuronal spread of measles virus across neurons. A fusion inhibitor peptide would be a valuable potential therapeutic option to treat SSPE.1

In conclusion, SSPE in older adults remains a diagnostic possibility both in resource-rich developed counties and in countries where measles is still endemic. SSPE in older patients is likely to present with atypical clinical features, and characteristic myoclonus and periodic EEG changes may not be present. A high index of suspicion and appropriate workup is essential for early diagnosis. There is a need to include cerebrospinal fluid antimeasles antibody titer estimation in the workup of progressive dementia, particularly in patients with myoclonus or periodic EEG abnormalities.

References

1. Garg RK, Mahadevan A, Malhotra HS, Rizvi I, Kumar N, Uniyal R. Subacute sclerosing panencephalitis. Rev Med Virol 2019:e2058. doi: 10.1002/rmv.2058. [Epub ahead of print]

2. World Health Organization. Subacute sclerosing panencephalitis and measles vaccination. Available from: https://www.who.int/vaccine_safety/committee/topics/measles_sspe/Jan_2006/en/ [cited 11 August 2019].

3. Prashanth LK, Taly AB, Ravi V, Sinha S, Arunodaya GR. Adult onset subacute sclerosing panencephalitis: clinical profile of 39 patients from a tertiary care centre. J Neurol Neurosurg Psychiatry 2006;77:630–633. doi: 10.1136/jnnp.2005.085829

4. Reyes AJ, Ramcharan K, Perot S, Giddings LG, Rampersad F, Gobin R. Subacute sclerosing panencephalitis causing rapidly progressive dementia and myoclonic jerks in a sexagenarian woman. Tremor Other Hyperkinet Mov 2019;9. doi: 10.7916/tohm.v0.680

5. Gokoglu A, Gozdas HT. Adult-onset subacute sclerosing panencephalitis presented with neuropsychiatric symptoms. J Coll Physicians Surg Pak 2019;29:S29–S30. doi: 10.29271/jcpsp.2019.06.S29

6. Elmali AD, Simsekoglu R, Sahin E, DumanIlki C, Uygun O, Coban O, Gurses C. Senile-onset subacute sclerosing panencephalitis, presenting with peculiar findings. Clin EEG Neurosci 2019;50:283–286. doi: 10.1177/1550059418793758

7. Tanaka J, Nakamura H, Fukada T. Adult-onset subacute sclerosing panencephalitis: immunocytochemical and electron microscopic demonstration of the viral antigen. Clin Neuropathol 1987;6:30–37.

8. Studart Neto A, Nóbrega PR, Duarte MI, Lucato LT, Castro LH, Nitrini R. Adult-onset subacute sclerosing panencephalitis manifesting as slowly progressive dementia. J Neurovirol 2015;21:468–471. doi: 10.1007/s13365-015-0336-0

9. Gagnon A, Bouchard RW. Fulminating adult-onset subacute sclerosing panencephalitis in a 49-year-old man. Arch Neurol 2003;60:1160–1161. doi: 10.1001/archneur.60.8.1160

10. Croxson MC, Anderson NE, Vaughan AA, Hutchinson DO, Schroeder BA, Cluroe AD, Hyatt AD. Subacute measles encephalitis in an immunocompetent adult. J Clin Neurosci 2002;9:600–604. doi: 10.1054/jocn.2001.1062

11. Dubois B, Lemmens R, Laffut W, Van Ranst M. Subacute sclerosing panencephalitis in the differential diagnosis of encephalitis. Neurology 2005;65:1145–1146. doi: 10.1212/WNL.65.7.1145-a

12. Baillif S, Tieulie N, Queyrel V, Cornut PL, Gastaud P. New aspects of viral necrotizing retinitis in subacute sclerosing panencephalitis with spectral-domainoptical coherence tomography. Retin Cases Brief Rep 2012;6:235–241. doi: 10.1097/ICB.0b013e318224779b

13. Frings M, Blaeser I, Kastrup O. Adult-onset subacute sclerosing panencephalitis presenting as a degenerative dementia syndrome. J Neurol 2002;249:942–943. doi: 10.1007/s00415-002-0720-6

14. Jeevagan V, Dissanayake A. Chorioretinitis: a potential clue to the early diagnosis of subacute sclerosing panencephalitis. Pract Neurol 2017;17:293–296. doi: 10.1136/practneurol-2017-001646

15. World Health Organization. New measles surveillance data for 2019. Available from: https://www.who.int/immunization/newsroom/measles-data-2019/en/ [cited 11 August 2019].